Pharma and proactive, preventative healthcare: how to use th...

Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare.

Disruption and maturity: the future directions for biologics

  Is the UK’s NHS saving enough from the new wave of biosimilars?

Powering pharma’s commercial teams with market access insigh...

When small becomes big: orphan medicines, advances, access a...

Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations.

Unlocking the value of pharmacists to reach the right patien...

Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers.

Approval and access: overcoming the final hurdle of drug dev...

2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater collaboration in health